A citation-based method for searching scientific literature

Yuliya Lytvyn, Petter Bjornstad, Daniel H van Raalte, Hiddo L Heerspink, David Z I Cherney. Endocr Rev 2020
Times Cited: 28







List of co-cited articles
222 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
75

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
560
46

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
39

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
35

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
35

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
32



Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
732
28

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.
Lennart Tonneijck, Marcel H A Muskiet, Mark M Smits, Erik J van Bommel, Hiddo J L Heerspink, Daniël H van Raalte, Jaap A Joles. J Am Soc Nephrol 2017
225
28

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
Erik J M van Bommel, Marcel H A Muskiet, Michaël J B van Baar, Lennart Tonneijck, Mark M Smits, Anna L Emanuel, Andrea Bozovic, A H Jan Danser, Frank Geurts, Ewout J Hoorn,[...]. Kidney Int 2020
94
28

Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.
Kengo Kidokoro, David Z I Cherney, Andrea Bozovic, Hajime Nagasu, Minoru Satoh, Eiichiro Kanda, Tamaki Sasaki, Naoki Kashihara. Circulation 2019
99
28

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
25

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
21

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Fady T Botros, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
166
21

Liraglutide and Renal Outcomes in Type 2 Diabetes.
Johannes F E Mann, David D Ørsted, Kirstine Brown-Frandsen, Steven P Marso, Neil R Poulter, Søren Rasmussen, Karen Tornøe, Bernard Zinman, John B Buse. N Engl J Med 2017
486
21

Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Hiddo J L Heerspink, Mikhail Kosiborod, Silvio E Inzucchi, David Z I Cherney. Kidney Int 2018
127
21

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews,[...]. Lancet Diabetes Endocrinol 2018
247
21

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
289
21

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
17

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
B M Brenner, M E Cooper, D de Zeeuw, W F Keane, W E Mitch, H H Parving, G Remuzzi, S M Snapinn, Z Zhang, S Shahinfar. N Engl J Med 2001
17

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Lancet Diabetes Endocrinol 2017
187
17

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.
Hiddo J L Heerspink, Paul Perco, Skander Mulder, Johannes Leierer, Michael K Hansen, Andreas Heinzel, Gert Mayer. Diabetologia 2019
101
17

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
David Z I Cherney, Claire C J Dekkers, Sean J Barbour, Daniel Cattran, Abdul Halim Abdul Gafor, Peter J Greasley, Gozewijn D Laverman, Soo Kun Lim, Gian Luca Di Tanna, Heather N Reich,[...]. Lancet Diabetes Endocrinol 2020
51
17

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
David Z I Cherney, Mark E Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Søren S Lund. Kidney Int 2018
95
17

Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
Claire C J Dekkers, Sergei Petrykiv, Gozewijn D Laverman, David Z Cherney, Ron T Gansevoort, Hiddo J L Heerspink. Diabetes Obes Metab 2018
97
17

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
736
17

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Katherine R Tuttle, Mark C Lakshmanan, Brian Rayner, Robert S Busch, Alan G Zimmermann, D Bradley Woodward, Fady T Botros. Lancet Diabetes Endocrinol 2018
186
14

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
E J Lewis, L G Hunsicker, W R Clarke, T Berl, M A Pohl, J B Lewis, E Ritz, R C Atkins, R Rohde, I Raz. N Engl J Med 2001
14

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurray. Lancet Diabetes Endocrinol 2019
399
14

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
323
14

The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
Anne C Hesp, Jennifer A Schaub, Pottumarthi V Prasad, Volker Vallon, Gozewijn D Laverman, Petter Bjornstad, Daniël H van Raalte. Kidney Int 2020
29
14

Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials.
David Z I Cherney, Hiddo J L Heerspink, Robert Frederich, Mario Maldonado, Jie Liu, Annpey Pong, Zhi J Xu, Shrita Patel, Anne Hickman, James P Mancuso,[...]. Diabetologia 2020
18
22

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Ofri Mosenzon, Stephen D Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L Goodrich, Sabina A Murphy, Hiddo J L Heerspink, Thomas A Zelniker, Jamie P Dwyer,[...]. Lancet Diabetes Endocrinol 2019
252
14

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
Ralph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani. Nat Rev Nephrol 2017
213
14

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome.
David Cherney, Bruce A Perkins, Yuliya Lytvyn, Hiddo Heerspink, María E Rodríguez-Ortiz, Harald Mischak. PLoS One 2017
16
25

Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial.
Mark E Cooper, Silvio E Inzucchi, Bernard Zinman, Stefan Hantel, Maximilian von Eynatten, Christoph Wanner, Audrey Koitka-Weber. Am J Kidney Dis 2019
25
16

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
512
14

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph,[...]. N Engl J Med 2020
188
14

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Yuliya Lytvyn, Petter Bjornstad, Jacob A Udell, Julie A Lovshin, David Z I Cherney. Circulation 2017
208
10

Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.
M H A Muskiet, L Tonneijck, M M Smits, M H H Kramer, M Diamant, J A Joles, D H van Raalte. Diabetes Obes Metab 2016
46
10

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.
Vlado Perkovic, Hiddo Lambers Heerspink, John Chalmers, Mark Woodward, Min Jun, Qiang Li, Stephen MacMahon, Mark E Cooper, Pavel Hamet, Michel Marre,[...]. Kidney Int 2013
181
10

Single-Nephron Glomerular Filtration Rate in Healthy Adults.
Aleksandar Denic, Jerry Mathew, Lilach O Lerman, John C Lieske, Joseph J Larson, Mariam P Alexander, Emilio Poggio, Richard J Glassock, Andrew D Rule. N Engl J Med 2017
133
10

Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule.
Thaissa Dantas Pessoa, Luciene Cristina Gastalho Campos, Luciene Carraro-Lacroix, Adriana C C Girardi, Gerhard Malnic. J Am Soc Nephrol 2014
89
10

The tubular hypothesis of nephron filtration and diabetic kidney disease.
Volker Vallon, Scott C Thomson. Nat Rev Nephrol 2020
61
10

Renal physiology of glucose handling and therapeutic implications.
David Z Cherney, Mehmet Kanbay, Julie A Lovshin. Nephrol Dial Transplant 2020
19
15

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.
Christopher P Cannon, Vlado Perkovic, Rajiv Agarwal, James Baldassarre, George Bakris, David M Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Hiddo J L Heerspink,[...]. Circulation 2020
49
10

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function.
Erik J M van Bommel, Yuliya Lytvyn, Bruce A Perkins, Nima Soleymanlou, Nora M Fagan, Audrey Koitka-Weber, Jaap A Joles, David Z I Cherney, Daniël H van Raalte. Kidney Int 2020
11
27

A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.
Yifan Zhang, Daisuke Nakano, Yu Guan, Hirofumi Hitomi, Akiyoshi Uemura, Tsutomu Masaki, Hideki Kobara, Takeshi Sugaya, Akira Nishiyama. Kidney Int 2018
59
10

Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus.
Volker Vallon, Michael Rose, Maria Gerasimova, Joseph Satriano, Kenneth A Platt, Hermann Koepsell, Robyn Cunard, Kumar Sharma, Scott C Thomson, Timo Rieg. Am J Physiol Renal Physiol 2013
227
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.